Prevention of Migraine During Prodrome With Naratriptan

Cephalalgia ◽  
2000 ◽  
Vol 20 (2) ◽  
pp. 122-126 ◽  
Author(s):  
R Luciani ◽  
D Carter ◽  
L Mannix ◽  
M Hemphill ◽  
M Diamond ◽  
...  
Keyword(s):  
Migraine Headache ◽  
Onset Time ◽  
Treatment Phase ◽  
Baseline Phase ◽  
Headache Severity ◽  
Headache Treatment ◽  
Headache Patients

Objective To determine the role of naratriptan in preventing migraine headache when administered during prodrome. Procedures Baseline phase: patients recorded prodrome symptoms and time of onset, time when patient knew that headache was inevitable, time of onset and severity of headache. Treatment phase: patients given naratriptan 2.5 mg to take at the time they knew headache was inevitable. Patients recorded prodrome symptoms and time of onset, time they knew headache was inevitable, time naratriptan administered, time of onset and severity of any headache. Patients treated three prodromes separated by at least 48 h. Findings Twenty patients completed both phases. During baseline phase, 59 prodromes were reported and all were followed by headache. Severity of headache: 5% mild, 51% moderate, 44% severe. During treatment phase, 63 prodromes were reported. Of these, 38/63 (60%) were not followed by headache. Among headaches that occurred, the majority occurred within 2 h of naratriptan administration, suggesting that naratriptan is more effective in preventing headache if taken early in prodrome. Severity of 25 headaches: 44% mild, 24% moderate, 32% severe. Conclusions Naratriptan 2.5 mg appears to prevent migraine headache when given early in prodrome. If headache occurs, severity appears to be reduced. □ Prodrome, premonitory, aura, naratriptan, migraine

scholarly journals ROLE OF TRANSCRANIAL DOPPLER IN DETECTING RIGHT TO LEFT CIRCULATORY SHUNTS IN MIGRAINE HEADACHE PATIENTS.

2018 ◽  
Vol 6 (12) ◽  
pp. 660-667
Author(s):  
Mohamed ORabie ◽  
◽  
Khaled HRashed ◽  
Mohamed ABasiouny ◽  
Suzan BAlHefnawy ◽  
...  
Keyword(s):  
Transcranial Doppler ◽  
Migraine Headache ◽  
Headache Patients

Plasma Calcitonin Gene-Related Peptide in Diagnosing and Predicting Paediatric Migraine

Cephalalgia ◽  
2009 ◽  
Vol 29 (8) ◽  
pp. 883-890 ◽  
Author(s):  
P-C Fan ◽  
P-H Kuo ◽  
S-H Chang ◽  
W-T Lee ◽  
R-M Wu ◽  
...  
Keyword(s):  
Migraine Headache ◽  
Paired Comparison ◽  
Calcitonin Gene Related Peptide ◽  
Enzyme Linked Immunosorbent Assay ◽  
Blood Samples ◽  
Related Peptide ◽  
Pediatric Migraine ◽  
Calcitonin Gene ◽  
Headache Patients

To investigate the role of plasma calcitonin gene-related peptide (CGRP) in paediatric migraine, we prospectively collected 134 blood samples during or between attacks from 66 migraine, 33 non-migraine headache (non-migraine) and 22 non-headache patients, aged 4–18 years. Plasma CGRP concentrations were measured by enzyme-linked immunosorbent assay and disability by Pediatric MIgraine Disability ASsessment (PedMIDAS) questionnaire. Migraineurs had higher plasma CGRP levels than non-migraine patients ( P = 0.007). The attack level was higher than the non-attack level in migraine ( P = 0.036), but not in non-migraine, patients. This was also revealed in paired comparison ( n = 9, P = 0.015 vs. n = 4, P = 0.47). Using a threshold of 55.1 pg/ml, the sensitivity of the attack level in predicting migraine was 0.81, and specificity 0.75. The PedMIDAS score tended to be higher in the high CGRP (> 200 pg/ml, n = 7) group than in the low (< 200 pg/ml, n = 33) group (26.07 vs. 19.32, P = 0.16) using Mann–Whitney test. Plasma CGRP is useful for diagnosis in paediatric migraine.

The role of migraine headache severity, associated features and interactions with overweight/obesity in inhibitory control

2017 ◽  
Vol 128 (1) ◽  
pp. 63-70 ◽  
Author(s):  
Rachel Galioto ◽  
Kevin C. O'Leary ◽  
John Gunstad ◽  
J. Graham Thomas ◽  
Richard B. Lipton ◽  
...  
Keyword(s):  
Inhibitory Control ◽  
Migraine Headache ◽  
Headache Severity

Involvement of Subcortical Structures in the Preparation of Self-Paced Movement

2004 ◽  
Vol 18 (2/3) ◽  
pp. 130-139 ◽  
Author(s):  
Guillermo Paradiso ◽  
Danny Cunic ◽  
Robert Chen
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Basal Ganglia ◽  
Onset Time ◽  
Movement Planning ◽  
Movement Preparation ◽  
Subcortical Structures ◽  
Postoperative Mri ◽  
Deep Brain

Abstract Although it has long been suggested that the basal ganglia and thalamus are involved in movement planning and preparation, there was little direct evidence in humans to support this hypothesis. Deep brain stimulation (DBS) is a well-established treatment for movement disorders such as Parkinson's disease, tremor, and dystonia. In patients undergoing DBS surgery, we recorded simultaneously from scalp contacts and from electrodes surgically implanted in the subthalamic nucleus (STN) of 13 patients with Parkinson's disease and in the “cerebellar” thalamus of 5 patients with tremor. The aim of our studies was to assess the role of the cortico-basal ganglia-thalamocortical loop through the STN and the cerebello-thalamocortical circuit through the “cerebellar” thalamus in movement preparation. The patients were asked to perform self-paced wrist extension movements. All subjects showed a cortical readiness potential (RP) with onset ranging between 1.5 to 2s before the onset of movement. Subcortical RPs were recorded in 11 of 13 with electrodes in the STN and in 4 of 5 patients with electrodes in the thalamus. The onset time of the STN and thalamic RPs were not significantly different from the onset time of the scalp RP. The STN and thalamic RPs were present before both contralateral and ipsilateral hand movements. Postoperative MRI studies showed that contacts with maximum RP amplitude generally were inside the target nucleus. These findings indicate that both the basal ganglia and the cerebellar circuits participate in movement preparation in parallel with the cortex.

scholarly journals Analytical and diagnostic performances of a high-throughput immunoassay for SARS-CoV-2 IgM and IgG

2020 ◽  
Author(s):  
Andrea Padoan ◽  
Chiara Cosma ◽  
Paolo Zaupa ◽  
Mario Plebani
Keyword(s):  
Sensitivity And Specificity ◽  
Symptom Onset ◽  
Severe Disease ◽  
Onset Time ◽  
Time Frame ◽  
Serum Samples ◽  
Time Period ◽  
Analytical Imprecision ◽  
Range Of Values

BackgroundAbstractReliable SARS-CoV-2 serological assays are required for diagnosing infections, for the serosurveillance of past exposures and for assessing the response to future vaccines. In this study, the analytical and clinical performances of a chemiluminescent immunoassays for SARS-CoV-2 IgM and IgG detection (Mindray CL-1200i), targeting Nucleocapsid (N) and receptor binding domain (RBD) portion of the Spike protein, were evaluated.MethodsPrecision and linearity were evaluated using standardized procedures. A total of 157 leftover serum samples from 81 hospitalized confirmed COVID-19 patients (38 with moderate and 43 with severe disease) and 76 SARS-CoV-2 negative subjects (44 healthcare workers, 20 individuals with rheumatic disorders, 12 pregnant women) were included in the study. In an additional series of 44 SARS-CoV-2 positive, IgM and IgG time kinetics were also evaluated in a time-period of 38 days.ResultsPrecision was below or equal to 4% for both IgM and IgG, in all the studied levels, whilst a slightly significant deviation from linearity was observed for both assays in the range of values covering the manufacturer’s cut-off. Considering a time frame ≥ 12 days post symptom onset, sensitivity and specificity for IgM were 92.3% (95%CI:79.1%-98.4%) and 92.1% (95%CI:83.6%-97.0%). In the same time frame, sensitivity and specificity for IgG were 100% (95%CI:91.0%-100%) and 93.4% (95%CI:85.3%-97.8%). The assays agreement was 73.9% (Cohen’s kappa of 0.373). Time kinetics showed a substantial overlapping of IgM and IgG response, the latter values being elevated up to 38 days from symptoms onset.ConclusionsAnalytical imprecision is satisfactory as well as the linearity, particularly when taking into account the fact that both assays are claimed to be qualitative. Diagnostic sensitivity of IgG was excellent, especially considering specimens collected ≥12 days post symptom onset. Time kinetics suggest that IgM and IgG are detectable early in the course of infection, but the role of SARS-CoV-2 antibodies in clinical practice still requires further evaluations.

scholarly journals Cures That (Make You) Work

2021 ◽  
Vol 229 (3) ◽  
pp. 171-177 ◽  
Author(s):  
Jana S. Aengenheister ◽  
Renée Urban ◽  
Georg Halbeisen
Keyword(s):  
Clinical Application ◽  
Social Perception ◽  
Social Role ◽  
Health Benefits ◽  
Behavioral Changes ◽  
Total N ◽  
Health Related Behaviors ◽  
Headache Treatment ◽  
Health Related

Abstract. Successful treatment not only depends on adhering to taking medication and attending therapy but also on behavioral changes. In two experiments (total N = 256), we investigated the hypothesis that the perceived social role of a treatment as partner (co-producer of a health-benefits) or servant (sole provider of health benefits) could promote or prevent intentions to engage in health-related behaviors. Specifically, we used headache treatment as an everyday example and found that participants were more inclined to engage in headache-reducing behaviors when painkillers were described as partners as compared to servants. Implications of these findings for the importance of anthropomorphic social perception in the clinical application are discussed.

scholarly journals Solute Driven Transient Convection in Layered Porous Media

2021 ◽  
pp. 3-9
Author(s):  
Emmanuel E. Luther ◽  
Seyed M. Shariatipour ◽  
Michael C. Dallaston ◽  
Ran Holtzman
Keyword(s):  
Convective Instability ◽  
Onset Time ◽  
Fluid Phase ◽  
Deep Saline Aquifer ◽  
Research Attention ◽  
Storage Security ◽  
Permeability Distribution ◽  
Layered Porous Media ◽  
Geological Formations

AbstractCO2 geological sequestration has been proposed as a climate change mitigation strategy that can contribute towards meeting the Paris Agreement. A key process on which successful injection of CO2 into deep saline aquifer relies on is the dissolution of CO2 in brine. CO2 dissolution improves storage security and reduces risk of leakage by (i) removing the CO2 from a highly mobile fluid phase and (ii) triggering gravity-induced convective instability which accelerates the downward migration of dissolved CO2. Our understanding of CO2 density-driven convection in geologic media is limited. Studies on transient convective instability are mostly in homogeneous systems or in systems with heterogeneity in the form of random permeability distribution or dispersed impermeable barriers. However, layering which exist naturally in sedimentary geological formations has not received much research attention on transient convection. Therefore, we investigate the role of layering on the onset time of convective instability and on the flow pattern beyond the onset time during CO2 storage. We find that while layering has no significant effect on the onset time, it has an impact on the CO2 flux. Our findings suggest that detailed reservoir characterisation is required to forecast the ability of a formation to sequester CO2.

Migraine and Antiphospholipid Antibodies

Cephalalgia ◽  
1992 ◽  
Vol 12 (2) ◽  
pp. 69-74 ◽  
Author(s):  
Gretchen E Tietjen
Keyword(s):  
Antiphospholipid Antibodies ◽  
Migraine Headache ◽  
Migraine Aura ◽  
Neurologic Symptoms ◽  
Actual Role

Migraine and antiphospholipid antibodies. Cephalalgia 1992:12:69–74. Antiphospholipid antibodies have been detected in patients with transient neurologic symptoms including migraine aura. The role of these antibodies in the pathogenesis of migraine is not fully understood. The available data suggest an association between the migraine-like phenomena and antiphospholipid antibodies, but not between migraine headache and antiphospholipid antibodies. To elucidate the actual role of antiphospholipid antibodies in migraine, prospective, controlled studies are needed.

scholarly journals Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial

2018 ◽  
Vol 36 (24) ◽  
pp. 2514-2523 ◽  
Author(s):  
Françoise Huguet ◽  
Sylvie Chevret ◽  
Thibaut Leguay ◽  
Xavier Thomas ◽  
Nicolas Boissel ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Standard Dose ◽  
Lymphoblastic Leukemia ◽  
Philadelphia Chromosome ◽  
Treatment Phase ◽  
Free Survival ◽  
Treatment Tolerance ◽  
To Receive

Purpose To evaluate randomly the role of hyperfractionated cyclophosphamide (hyper-C) dose intensification in adults with newly diagnosed Philadelphia chromosome–negative acute lymphoblastic leukemia treated with a pediatric-inspired protocol and to determine the upper age limit for treatment tolerability in this context. Patients and Methods A total of 787 evaluable patients (B/T lineage, 525 and 262, respectively; median age, 36.1 years) were randomly assigned to receive a standard dose of cyclophosphamide or hyper-C during first induction and late intensification. Compliance with chemotherapy was assessed by median doses actually received during each treatment phase by patients potentially exposed to the full planned doses. Results Overall complete remission (CR) rate was 91.9%. With a median follow-up of 5.2 years, the 5-year rate of event-free survival (EFS) and overall survival (OS) was 52.2% (95% CI, 48.5% to 55.7%) and 58.5% (95% CI, 54.8% to 61.9%), respectively. Randomization to the hyper-C arm did not increase the CR rate or prolong EFS or OS. As a result of worse treatment tolerance, advanced age continuously affected CR rate, EFS, and OS, with 55 years as the best age cutoff. At 5 years, EFS was 55.7% (95% CI, 51.8% to 59.4%) for patients younger than 55 years of age versus 25.8% (95% CI, 19.9% to 35.6%) in older patients (hazard ratio, 2.16; P < .001). Patients ≥ 55 years of age, in whom a lower compliance to the whole planned chemotherapy was observed, benefited significantly from hyper-C, whereas younger patients did not. Conclusion No significant benefit was associated with the introduction of a hyper-C sequence into a frontline pediatric-like adult acute lymphoblastic leukemia therapy. Overall, tolerability of an intensive pediatric-derived treatment was poor in patients ≥ 55 years of age.

Sign in / Sign up

Export Citation Format

Share Document